Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Updates in the ALK-Positive NSCLC Paradigm

March 23rd 2020

Advanced, recurrent, and metastatic NSCLC is often associated with poor prognosis, and treatment is aimed to extend survival and provide symptom management.

Research Aims to Augment OS Benefit With Osimertinib in EGFR+ NSCLC

March 23rd 2020

Erin M. Bertino, MD, discusses the current treatment landscape and next steps in the EGFR-mutant NSCLC paradigm.

Biomarker Hunt Garners Interest Amid New Standard of Care in NSCLC

March 21st 2020

Terence M. Williams, MD, PhD, discusses the impact of the PACIFIC trial on stage III NSCLC and how the hunt for prognostic biomarkers is underway across the lung cancer paradigm.

Biomarkers Inform Immunotherapy Decisions in Advanced NSCLC

March 20th 2020

Balazs Halmos, MD, MA, discusses the advances that have been made in the treatment of patients with metastatic non–small cell lung cancer, ongoing biomarker research, and the importance of molecular testing.

Building On Immunotherapy, Preventing Acquired Resistance Are Next Steps in Lung Cancer Research

March 20th 2020

David P. Carbone, MD, PhD, discusses advances in immunotherapy and targeted therapy in non–small cell lung cancer and ongoing research efforts focused on acquired resistance to available therapies.

Proton Therapy Offers More Precision in Lung Cancer, But Lacks Accessibility

March 20th 2020

Terence T. Sio, MD, MS, discusses the utility of proton therapy in lung cancer.

Almonertinib Approved in China for EGFR T79M+ NSCLC

March 19th 2020

The Chinese National Medical Products Administration has approved almonertinib (Ameile; HS-10296) for the treatment of patients with EGFR T790M mutation–positive non–small cell lung cancer who have progressed on or after other EGFR TKI therapy.

Treatments for Oncogenic-Driven Lung Cancer Continue to Expand

March 18th 2020

Anastasios Dimou, MD, discusses available and emerging treatment options and approaches for patients with oncogenic-driven lung cancer.

Spotlighting New Standards of Care in Lung Cancer in Summit

March 18th 2020

We recently traveled to Summit, New Jersey for a State of the Science Summit on Lung Cancer, which featured insights from Memorial Sloan Kettering Cancer Center faculty.

Immunotherapy, Targeted Agents Transform Lung Cancer Paradigm, But Challenges Remain

March 17th 2020

Chad Cherington, MD, discusses groundbreaking developments and critical next steps across the spectrum in lung cancer.

Durvalumab/Chemo OS Benefit Sustained in ES-SCLC, But Durvalumab/Tremelimumab Regimen Falls Short

March 17th 2020

Combining durvalumab with standard frontline chemotherapies showed a sustained overall survival benefit in patients with extensive-stage small cell lung cancer, but a regimen of durvalumab, chemotherapy, and tremelimumab did not boost OS.

ctDNA Advances Perpetuate Progress Achieved With Osimertinib in EGFR+ NSCLC

March 17th 2020

Balazs Halmos, MD, discusses the implications of the emergence of osimertinib in the frontline treatment of patients with EGFR-mutated non–small cell lung cancer, the efforts being made to address resistance to the third-generation EGFR TKI, and the promise of circulating tumor DNA in the space.

Introduction of Immunotherapy Initiates Change in Squamous NSCLC

March 16th 2020

Panayiotis S. Savvides, MD, discusses the results of the KEYNOTE-407 and IMpower131 trials and how the data have impacted the treatment of patients with stage IV squamous non–small cell lung cancer.

Dr. D'Cunha on Surgical Options for High-Risk Patients With Lung Cancer

March 14th 2020

Jonathan D'Cunha, MD, PhD, FACS, discusses surgical options for high-risk patients with lung cancer.

Dr. Cherington on the Use of Immunotherapy and Targeted Therapy in Lung Cancer

March 14th 2020

Chad Cherington, MD, discusses the use of immunotherapy and targeted therapy in lung cancer.

Dr. Raez on the Benefits of Liquid Biopsies in Newly Diagnosed Lung Cancer

March 13th 2020

Luis E. Raez, MD, discusses the role of liquid biopsies in newly diagnosed patients with lung cancer.

Dr. Sio on Optimal Radiation Therapy Dose in Locally Advanced NSCLC

March 13th 2020

Terence T. Sio, MD, MS, discusses the standard-of-care dose of radiation therapy in locally advanced, non–small cell lung cancer.

Dr. Gould on the Implications of the NELSON Trial in Lung Cancer

March 11th 2020

Michael K. Gould, MD, MS, pulmonologist and director of the Division of Health Services Research and Implementation Science at Kaiser Permanente Southern California, discusses the implications of the NELSON trial in lung cancer.

FDA Grants Breakthrough Designation to JNJ-6372 for EGFR Exon 20-Mutant NSCLC

March 11th 2020

The FDA has granted a breakthrough therapy designation to JNJ-61186372 for the treatment of patients with EGFR-positive metastatic non–small cell lung cancer who harbor exon 20 insertion mutations, and whose disease has progressed on or after platinum-based chemotherapy.

Dr. Mirhadi on Patient Populations of Lung Cancer Optimal for Radiation

March 4th 2020

Amin J. Mirhadi, MD, discusses patient populations of lung cancer who should be treated with radiation therapy.